-
Adherence
-
Children
-
Clinical reviews
-
Drug supply
-
Guidelines
-
Hepatitis and HIV coinfection
-
HIV Testing
-
Infant feeding
-
Laboratory monitoring
- Defining, and then watching for, treatment failure - 10/9/2007
- Cheap viral load test is urgently needed for resource-poor settings, say treatment advocates - 11/1/2007
- Scaling up laboratory capacity for the coming storm of XDR-TB, and why the HIV treating community must get involved now - 28/11/2006
- Lowering the threshold - Is there a case for re-evaluating eligibility criteria for ART? - 1/11/2006
- Monitoring antiretroviral treatment with limited laboratory services - 20/6/2006
- Laboratory requirements for scaling up HIV treatment - 27/10/2005
- Symptoms versus laboratory monitoring as criteria for starting treatment - 27/10/2005
-
Malaria & HIV
-
Mental health and HIV
-
Neurological problems, including HIV dementia
-
Nutrition
-
Palliative care
-
Prevention
-
Prevention of mother-to child transmission
-
Scaling up treatment and models of service delivery
-
Side-effects
-
South Africa
-
Starting treatment
-
Stigma
-
Task shifting
-
Treatment failure
-
Tuberculosis
-
Viral load testing
feedback
Give us your views on our work
Laboratory monitoring
-
Defining, and then watching for, treatment failure - 10/9/2007
-
Cheap viral load test is urgently needed for resource-poor settings, say treatment advocates - 11/1/2007
-
Scaling up laboratory capacity for the coming storm of XDR-TB, and why the HIV treating community must get involved now - 28/11/2006
-
Lowering the threshold - Is there a case for re-evaluating eligibility criteria for ART? - 1/11/2006
-
Monitoring antiretroviral treatment with limited laboratory services - 20/6/2006
-
Laboratory requirements for scaling up HIV treatment - 27/10/2005
-
Symptoms versus laboratory monitoring as criteria for starting treatment - 27/10/2005
About HATIP
A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.
Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.
Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.
latest aidsmap news
- Multiple treatment failures occur less frequently but remain associated with high mortality rates in North American cohort
- People with HIV providing high quality treatment support in community
- International donors must not retreat from commitment to HIV treatment scale-up, MSF warns
- Reassurance for HIV-positive women about short-term risk of bone loss
- Circumcision protects gay men who have a 'preference' for insertive sex from HIV
- Certain manifestations of stigma especially hurtful for people with HIV
- GSK and Pfizer launch joint HIV venture, ViiV Healthcare
- New hepatitis C protease inhibitors achieve 80% ‘cure’ rate in patients with genotype 1 infection
- President Obama announces US HIV travel ban will end in January 2010
- Darunavir/ritonavir, etravirine and raltegravir combination has 'remarkable' success in children with resistant virus